Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study
Cancers · 25.05.2026 · 18 (11) · 1722
DOI: 10.3390/cancers18111722 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 25.05.2026. Verfasst von Branko Dujovic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Dermatovenerology, Military Medical Academy, University of Defense, 11000 Belgrade, Serbia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia.
Abstract (Originalsprache)
Background/Objectives: This study evaluates the prognostic value of baseline inflammatory biomarkers, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV) in advanced cutaneous melanoma treated with first-line immunotherapy.
Methods
This multicenter retrospective study included 162 patients with unresectable stage III/IV cutaneous melanoma treated with first-line pembrolizumab, nivolumab, or nivolumab plus ipilimumab. Biomarkers were calculated from complete blood counts obtained within 30 days before treatment start. Cut-offs were defined by ROC analysis. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression. Response was assessed by RECIST v1.1.
Results
Higher baseline NLR, PLR, MLR, SII, and PIV were more common in patients with adverse baseline features, including liver metastases, elevated LDH, and poorer ECOG performance status. Patients with biomarker values below the cut-offs had significantly longer PFS and OS. In biomarker-specific multivariable models adjusted for selected clinical covariates, PIV retained the most consistent association with PFS and OS, while MLR was associated with PFS, and PLR with OS.
Conclusions
Baseline inflammatory biomarkers from routine blood counts provide useful prognostic information in advanced melanoma treated with first-line ICIs. PIV showed the most consistent association with survival outcomes and may support initial risk stratification alongside LDH, ECOG, and metastasis pattern. However, prospective validation in independent cohorts is needed before routine clinical implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic for Dermatovenerology, Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.
- Faculty of Medicine, Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.
- Clinic for Oncology, Clinical Centre of Niš, 18000 Niš, Serbia.
- Clinic of Oncology, Clinical Center University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina.
- Centre for Clinical Pharmacology, Military Medical Academy, 11000 Belgrade, Serbia.
- Alcedis, a HUMA Company, 35394 Giessen, Germany.
ORCID-Profile: Branko Dujovic, Aleksandar Popovic, Igor Salatic, Jovana Pavlica, Tanja Mesti, Muamer Terzo, Emina Bicakcic Filipovic, Lidija Kandolf
Förderung
- Science Fund of the Republic of Serbia
Zitieren
APA
Dujovic, B., Popovic, A., Jalovcic Suljevic, A., Cikota-Aleksic, B., Balic, M., Salatic, I., Pavlica, J., Schnecko, P., Mesti, T., Terzo, M., Bicakcic Filipovic, E., & Kandolf, L. (2026). Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study. Cancers, 18(11), 1722. https://doi.org/10.3390/cancers18111722
Vancouver
Dujovic B, Popovic A, Jalovcic Suljevic A, Cikota-Aleksic B, Balic M, Salatic I, et al. Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study. Cancers. 2026;18(11):1722. doi:10.3390/cancers18111722
BibTeX
@article{Dujovic2026,
author = {Dujovic, Branko and Popovic, Aleksandar and Jalovcic Suljevic, Amina and Cikota-Aleksic, Bojana and Balic, Mirjana and Salatic, Igor and Pavlica, Jovana and Schnecko, Philipp and Mesti, Tanja and Terzo, Muamer and Bicakcic Filipovic, Emina and Kandolf, Lidija},
title = {Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1722},
doi = {10.3390/cancers18111722}
}
EUVIMED